Pack your bags, Owls. Photo via Rice.edu

Rice University owls are flapping their wings across the Atlantic Ocean in order to open some doors to global education and research opportunities in Europe.

The university announced in a press release that the Rice University Paris Center is holding its ceremonial launch on Wednesday, June 29. The new facility will be housed in a historic 16th-century building in Paris and will be home to Rice-organized student programs, independent researchers, and international conferences, as well as a satellite and hub for other European research activity.

“The ambitions of our university and the needs of the future leaders we are educating require global engagement and perspective,” says outgoing Rice President David Leebron in the release. “The opening of this dedicated overseas facility represents the next step in the long-standing plan we have been pursuing to internationalize Rice and the Rice experience in every dimension.

"This has included welcoming more international students to our campus in Houston, fostering international travel and programs by our students and faculty, and building strong relationships with the best universities across the globe," he continues. "The Paris location offers an incredible range of opportunities, in fields ranging from art and architecture to international business and global relations and politics.”

The Rice University Paris Center will be located in Le Marais in the Hotel de La Faye, a 1500s hôtel particulier that was listed as a historic monument in 1966.

Caroline Levander, currently Rice’s vice president for global and digital strategy, was key in making the new center a reality and will oversee the Rice University Paris Center in her new role as vice president global.

“For our purposes, this building is an ideal educational space conveniently situated in one of the most historically significant areas of Paris,” Levander says in the release. “It looks and feels like a private university campus in the heart of a European capital city, and it reflects how Rice plans to expand its international impact in the coming years.”

Sylvester Turner and a delegation of civic and business leaders from the Greater Houston Partnership will attend the announcement in Paris this week. Per the release, the center, which will have six classroom spaces of various sizes that can accommodate around 125 students, is expected to be ready in January.

“Rice University’s mission statement commits us not only to pathbreaking research and unsurpassed teaching, but also to the betterment of our world,” says Provost Reginald DesRoches, who will transition to Rice’s president in July, in the release. “We’re eager to extend that mission internationally, and the opening of the Rice University Paris Center demonstrates that commitment.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."